All In Biotech

Drug Trial Radar · NCT02522650

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease

Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 2013

Primary completion

Oct 2021

Study completion Oct 2021

Sponsor

Lead sponsor
Georgetown UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.

Conditions

  • Proteinuria

Interventions

  • AmilorideDrug

    5mg twice a day for 8 weeks

  • TriamtereneDrug

    50mg twice a day for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24 hr urine protein excretionTime frame: 20 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.